Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment - Seite 4

Release authorized by the Chief Executive.

For further information, please contact:

Media Julie Meldrum T: [phone] E:[e-mail]	Kristen Bothwell T: [phone] E:[e-mail]
Investors Schond Greenway [phone] E: [e-mail]	Paul Hughes  T: [phone] E: [e-mail]